» Articles » PMID: 20488311

5-year Prognostic Value of No-reflow Phenomenon After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction

Overview
Date 2010 May 22
PMID 20488311
Citations 147
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The objective of this study was to investigate the impact of no-reflow phenomenon on 5-year mortality among patients with acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI). This impact was also assessed in relation to infarct size.

Background: The impact of no-reflow on long-term mortality in patients with STEMI has been insufficiently studied.

Methods: This study included 1,406 patients with STEMI treated by primary PCI. No-reflow was diagnosed using angiographic criteria. Infarct size was measured with single-photon emission computed tomography imaging 7 to 14 days after the acute event. The primary outcome was 5-year mortality.

Results: The no-reflow phenomenon was diagnosed in 410 patients (29%). Infarct size was 15.0% (6.0% to 29.0%) of the left ventricle in the no-reflow group versus 8.0% (2.0% to 21.0%) of the left ventricle in the reflow group (p < 0.001). There were 132 deaths during follow-up. Of them, 59 deaths occurred among patients with no-reflow and 73 deaths occurred among patients with reflow (Kaplan-Meier estimates of 5-year mortality 18.2% and 9.5%, respectively; odds ratio: 2.02; 95% confidence interval: 1.44 to 2.82; p < 0.001). The Cox proportional hazards model adjusting for infarct size among other variables identified the no-reflow phenomenon as an independent correlate of 5-year mortality (hazard ratio: 1.66; 95% confidence interval: 1.17 to 2.36; p = 0.004).

Conclusions: In patients with STEMI treated by primary PCI, no-reflow phenomenon is a strong predictor of 5-year mortality. No-reflow phenomenon after PCI provides prognostic information that is independent of and beyond that provided by infarct size.

Citing Articles

Protective role of Tongxinluo in mitigating myocardial fibrosis in mice with acute myocardial infarction via neuregulin-1 upregulation and Inhibition of endothelium-interstitial transition.

Li Z, Yin Y, Wei Y, Liu Y, Han N, Wang X J Mol Histol. 2025; 56(2):103.

PMID: 40063284 PMC: 11893718. DOI: 10.1007/s10735-025-10378-7.


Coronary Microvascular Dysfunction and Vasospastic Angina-Pathophysiology, Diagnosis and Management Strategies.

Abramik J, Mariathas M, Felekos I J Clin Med. 2025; 14(4).

PMID: 40004660 PMC: 11856034. DOI: 10.3390/jcm14041128.


Atherogenic index of plasma and coronary artery disease: a systematic review and meta-analysis of observational studies.

Assempoor R, Daneshvar M, Taghvaei A, Abroy A, Azimi A, Nelson J Cardiovasc Diabetol. 2025; 24(1):35.

PMID: 39844262 PMC: 11756160. DOI: 10.1186/s12933-025-02582-2.


The influence between plaque rupture and non-plaque rupture on clinical outcomes in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: a prospective cohort study.

Yang X, Yang J, Kashima Y, Hachinohe D, Sugie T, Xu S J Thorac Dis. 2024; 16(11):7771-7786.

PMID: 39678843 PMC: 11635223. DOI: 10.21037/jtd-24-1482.


SCAI Expert Consensus Statement on the Management of Patients With STEMI Referred for Primary PCI.

Tamis-Holland J, Abbott J, Al-Azizi K, Barman N, Bortnick A, Cohen M J Soc Cardiovasc Angiogr Interv. 2024; 3(11):102294.

PMID: 39649824 PMC: 11624394. DOI: 10.1016/j.jscai.2024.102294.